These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 22988868)

  • 1. LRRK2 GTPase dysfunction in the pathogenesis of Parkinson's disease.
    Xiong Y; Dawson VL; Dawson TM
    Biochem Soc Trans; 2012 Oct; 40(5):1074-9. PubMed ID: 22988868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural basis for Parkinson's disease-linked LRRK2's binding to microtubules.
    Snead DM; Matyszewski M; Dickey AM; Lin YX; Leschziner AE; Reck-Peterson SL
    Nat Struct Mol Biol; 2022 Dec; 29(12):1196-1207. PubMed ID: 36510024
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leucine-rich repeat kinase 2 (LRRK2)/PARK8 possesses GTPase activity that is altered in familial Parkinson's disease R1441C/G mutants.
    Li X; Tan YC; Poulose S; Olanow CW; Huang XY; Yue Z
    J Neurochem; 2007 Oct; 103(1):238-47. PubMed ID: 17623048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biochemical and molecular features of LRRK2 and its pathophysiological roles in Parkinson's disease.
    Seol W
    BMB Rep; 2010 Apr; 43(4):233-44. PubMed ID: 20423607
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Cell Biology of LRRK2 in Parkinson's Disease.
    Usmani A; Shavarebi F; Hiniker A
    Mol Cell Biol; 2021 Apr; 41(5):. PubMed ID: 33526455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Contribution of GTPase activity to LRRK2-associated Parkinson disease.
    Tsika E; Moore DJ
    Small GTPases; 2013; 4(3):164-70. PubMed ID: 24025585
    [TBL] [Abstract][Full Text] [Related]  

  • 7. GTPase activity and neuronal toxicity of Parkinson's disease-associated LRRK2 is regulated by ArfGAP1.
    Stafa K; Trancikova A; Webber PJ; Glauser L; West AB; Moore DJ
    PLoS Genet; 2012; 8(2):e1002526. PubMed ID: 22363216
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Parkinson's disease kinase LRRK2 autophosphorylates its GTPase domain at multiple sites.
    Greggio E; Taymans JM; Zhen EY; Ryder J; Vancraenenbroeck R; Beilina A; Sun P; Deng J; Jaffe H; Baekelandt V; Merchant K; Cookson MR
    Biochem Biophys Res Commun; 2009 Nov; 389(3):449-54. PubMed ID: 19733152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. LRRK2 and autophagy: a common pathway for disease.
    Manzoni C
    Biochem Soc Trans; 2012 Oct; 40(5):1147-51. PubMed ID: 22988880
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2.
    Biosa A; Trancikova A; Civiero L; Glauser L; Bubacco L; Greggio E; Moore DJ
    Hum Mol Genet; 2013 Mar; 22(6):1140-56. PubMed ID: 23241358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The R1441C mutation of LRRK2 disrupts GTP hydrolysis.
    Lewis PA; Greggio E; Beilina A; Jain S; Baker A; Cookson MR
    Biochem Biophys Res Commun; 2007 Jun; 357(3):668-71. PubMed ID: 17442267
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The biology and pathobiology of LRRK2: implications for Parkinson's disease.
    Moore DJ
    Parkinsonism Relat Disord; 2008; 14 Suppl 2():S92-8. PubMed ID: 18602856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The GTPase function of LRRK2.
    Taymans JM
    Biochem Soc Trans; 2012 Oct; 40(5):1063-9. PubMed ID: 22988866
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LRRK2 Structure-Based Activation Mechanism and Pathogenesis.
    Zhang X; Kortholt A
    Biomolecules; 2023 Mar; 13(4):. PubMed ID: 37189360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease.
    Greggio E
    Biochem Soc Trans; 2012 Oct; 40(5):1058-62. PubMed ID: 22988865
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular processes associated with LRRK2 function and dysfunction.
    Wallings R; Manzoni C; Bandopadhyay R
    FEBS J; 2015 Aug; 282(15):2806-26. PubMed ID: 25899482
    [TBL] [Abstract][Full Text] [Related]  

  • 17. LRRK2 pathobiology in Parkinson's disease.
    Martin I; Kim JW; Dawson VL; Dawson TM
    J Neurochem; 2014 Dec; 131(5):554-65. PubMed ID: 25251388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of LRRK2 kinase dysfunction in Parkinson disease.
    Kumar A; Cookson MR
    Expert Rev Mol Med; 2011 Jun; 13():e20. PubMed ID: 21676337
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenic LRRK2 mutations, through increased kinase activity, produce enlarged lysosomes with reduced degradative capacity and increase ATP13A2 expression.
    Henry AG; Aghamohammadzadeh S; Samaroo H; Chen Y; Mou K; Needle E; Hirst WD
    Hum Mol Genet; 2015 Nov; 24(21):6013-28. PubMed ID: 26251043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Leucine-rich repeat kinase 2 mutations and Parkinson's disease: three questions.
    Greggio E; Cookson MR
    ASN Neuro; 2009 Apr; 1(1):. PubMed ID: 19570025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.